Investment Snapshot
Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.
Share Price and Basic Stock Data
Last Updated: April 2, 2026, 3:37 am
| PEG Ratio | -1.23 |
|---|
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Sanofi India Ltd | 7,513 Cr. | 3,262 | 6,718/3,151 | 21.7 | 326 | 2.30 % | 57.5 % | 43.0 % | 10.0 |
| Marksans Pharma Ltd | 7,615 Cr. | 168 | 271/155 | 21.1 | 59.3 | 0.48 % | 20.0 % | 16.8 % | 1.00 |
| Shilpa Medicare Ltd | 7,328 Cr. | 375 | 502/260 | 41.4 | 125 | 0.13 % | 7.82 % | 4.21 % | 1.00 |
| Procter & Gamble Health Ltd | 7,983 Cr. | 4,809 | 6,739/4,725 | 27.2 | 373 | 2.60 % | 47.8 % | 36.4 % | 10.0 |
| Sequent Scientific Ltd | 8,768 Cr. | 201 | 260/111 | 203 | 32.2 | 0.00 % | 8.47 % | 3.21 % | 2.00 |
| Industry Average | 19,815.15 Cr | 1,053.84 | 53.84 | 201.20 | 0.39% | 16.35% | 15.16% | 6.10 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 672 | 736 | 515 | 491 | 469 | 511 | 464 | 524 | 515 | 536 | 406 | 475 | 420 |
| Expenses | 505 | 507 | 393 | 377 | 370 | 374 | 348 | 404 | 397 | 364 | 311 | 341 | 330 |
| Operating Profit | 167 | 230 | 122 | 114 | 100 | 137 | 116 | 120 | 118 | 172 | 95 | 134 | 90 |
| OPM % | 25% | 31% | 24% | 23% | 21% | 27% | 25% | 23% | 23% | 32% | 23% | 28% | 22% |
| Other Income | 34 | 44 | 57 | 82 | 77 | 41 | 21 | 2 | 14 | 3 | 9 | -22 | 3 |
| Interest | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 10 | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 9 | 9 | 10 |
| Profit before tax | 190 | 264 | 169 | 186 | 167 | 169 | 127 | 113 | 122 | 165 | 94 | 102 | 83 |
| Tax % | 31% | 28% | 27% | 18% | 18% | 19% | 19% | 27% | 25% | 28% | 26% | 26% | 26% |
| Net Profit | 131 | 190 | 123 | 152 | 138 | 137 | 103 | 82 | 91 | 120 | 70 | 76 | 62 |
| EPS in Rs | 56.91 | 82.78 | 53.43 | 66.17 | 59.87 | 59.39 | 44.96 | 35.74 | 39.70 | 51.96 | 30.22 | 33.04 | 26.83 |
Last Updated: March 3, 2026, 2:56 pm
Profit & Loss - Annual Report
Last Updated: February 25, 2026, 5:16 pm
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,809 | 1,977 | 2,193 | 2,367 | 2,460 | 2,771 | 3,071 | 2,902 | 2,957 | 2,770 | 2,851 | 2,013 | 1,932 |
| Expenses | 1,411 | 1,639 | 1,817 | 1,832 | 1,921 | 2,146 | 2,403 | 2,186 | 2,194 | 2,066 | 2,047 | 1,522 | 1,413 |
| Operating Profit | 398 | 339 | 376 | 535 | 538 | 625 | 667 | 716 | 762 | 704 | 804 | 491 | 519 |
| OPM % | 22% | 17% | 17% | 23% | 22% | 23% | 22% | 25% | 26% | 25% | 28% | 24% | 27% |
| Other Income | 83 | 131 | 218 | 66 | 79 | 88 | 33 | 45 | 564 | 204 | 83 | 79 | 4 |
| Interest | 0 | 0 | 0 | 2 | 1 | 1 | 0 | 2 | 2 | 2 | 2 | 2 | 2 |
| Depreciation | 92 | 97 | 113 | 119 | 102 | 103 | 100 | 82 | 67 | 42 | 40 | 37 | 37 |
| Profit before tax | 388 | 373 | 481 | 480 | 515 | 610 | 600 | 677 | 1,258 | 864 | 846 | 531 | 484 |
| Tax % | 32% | 29% | 33% | 37% | 37% | 38% | 31% | 29% | 25% | 28% | 29% | 22% | |
| Net Profit | 265 | 264 | 322 | 304 | 326 | 381 | 414 | 478 | 944 | 621 | 603 | 414 | 356 |
| EPS in Rs | 115.30 | 114.61 | 139.78 | 132.26 | 141.74 | 165.48 | 180.09 | 207.65 | 410.61 | 269.83 | 262.26 | 179.78 | 154.92 |
| Dividend Payout % | 39% | 39% | 46% | 51% | 50% | 51% | 194% | 176% | 119% | 211% | 64% | 65% |
Growth
Last Updated: September 5, 2025, 1:25 pm
Balance Sheet
Last Updated: August 11, 2025, 2:43 pm
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 | 23 |
| Reserves | 1,324 | 1,463 | 1,604 | 1,860 | 2,003 | 2,196 | 2,419 | 2,096 | 2,203 | 1,253 | 992 | 838 | 759 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23 | 25 | 24 | 19 | 19 | 21 |
| Other Liabilities | 532 | 742 | 778 | 658 | 751 | 765 | 802 | 777 | 811 | 772 | 681 | 732 | 436 |
| Total Liabilities | 1,878 | 2,228 | 2,405 | 2,541 | 2,778 | 2,984 | 3,244 | 2,918 | 3,061 | 2,072 | 1,715 | 1,612 | 1,239 |
| Fixed Assets | 699 | 648 | 877 | 817 | 769 | 733 | 499 | 464 | 334 | 306 | 315 | 312 | 309 |
| CWIP | 136 | 210 | 22 | 34 | 30 | 21 | 17 | 10 | 13 | 24 | 16 | 18 | 16 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Other Assets | 1,043 | 1,369 | 1,505 | 1,690 | 1,978 | 2,230 | 2,728 | 2,444 | 2,714 | 1,743 | 1,382 | 1,281 | 914 |
| Total Assets | 1,878 | 2,228 | 2,405 | 2,541 | 2,778 | 2,984 | 3,244 | 2,918 | 3,061 | 2,072 | 1,715 | 1,612 | 1,239 |
Cash Flow
| Month | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 398.00 | 339.00 | 376.00 | 535.00 | 538.00 | 625.00 | 667.00 | 693.00 | 737.00 | 680.00 | 785.00 | 472.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 24 | 21 | 24 | 22 | 29 | 21 | 27 | 19 | 18 | 17 | 24 | 42 |
| Inventory Days | 151 | 179 | 173 | 169 | 151 | 154 | 127 | 107 | 110 | 125 | 254 | 186 |
| Days Payable | 83 | 122 | 81 | 79 | 119 | 110 | 100 | 93 | 105 | 109 | 112 | 151 |
| Cash Conversion Cycle | 92 | 78 | 115 | 112 | 61 | 65 | 54 | 33 | 22 | 33 | 167 | 77 |
| Working Capital Days | 43 | 26 | 9 | 79 | 17 | 18 | 35 | -8 | -20 | -19 | 35 | 20 |
| ROCE % | 29% | 22% | 26% | 27% | 26% | 29% | 28% | 32% | 35% | 41% | 44% | 49% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| SBI Contra Fund | 251,576 | 0.21 | 101.08 | 161,000 | 2025-12-07 15:45:16 | 56.26% |
| Nippon India Pharma Fund | 230,272 | 1.17 | 92.52 | 236,008 | 2025-12-08 04:19:42 | -2.43% |
| Nippon India Growth Mid Cap Fund | 226,766 | 0.22 | 91.11 | N/A | N/A | N/A |
| Nippon India Small Cap Fund | 213,992 | 0.13 | 85.98 | 196,342 | 2025-12-08 07:42:13 | 8.99% |
| Nippon India Multi Cap Fund | 152,371 | 0.13 | 61.22 | 152,371 | 2025-04-22 17:25:21 | 0% |
| SBI ELSS Tax Saver Fund | 147,988 | 0.19 | 59.46 | N/A | N/A | N/A |
| SBI Midcap Fund | 128,577 | 0.23 | 51.66 | 195,082 | 2026-01-26 05:01:22 | -34.09% |
| Nippon India Innovation Fund | 49,110 | 0.73 | 19.73 | N/A | N/A | N/A |
| Sundaram Dividend Yield Fund | 11,397 | 0.51 | 4.58 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Dec 24 | Dec 23 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 179.46 | 261.78 |
| Diluted EPS (Rs.) | 179.46 | 261.78 |
| Cash EPS (Rs.) | 195.65 | 279.35 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 374.17 | 441.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 374.17 | 441.39 |
| Revenue From Operations / Share (Rs.) | 875.30 | 1239.61 |
| PBDIT / Share (Rs.) | 220.57 | 377.83 |
| PBIT / Share (Rs.) | 204.61 | 360.61 |
| PBT / Share (Rs.) | 187.57 | 367.61 |
| Net Profit / Share (Rs.) | 179.69 | 262.13 |
| NP After MI And SOA / Share (Rs.) | 179.69 | 262.13 |
| PBDIT Margin (%) | 25.19 | 30.47 |
| PBIT Margin (%) | 23.37 | 29.09 |
| PBT Margin (%) | 21.42 | 29.65 |
| Net Profit Margin (%) | 20.52 | 21.14 |
| NP After MI And SOA Margin (%) | 20.52 | 21.14 |
| Return on Networth / Equity (%) | 48.02 | 59.38 |
| Return on Capital Employeed (%) | 52.72 | 77.98 |
| Return On Assets (%) | 25.64 | 35.15 |
| Asset Turnover Ratio (%) | 1.21 | 0.00 |
| Current Ratio (X) | 1.57 | 1.92 |
| Quick Ratio (X) | 0.87 | 0.89 |
| Inventory Turnover Ratio (X) | 0.60 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 139.85 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 131.23 |
| Earning Retention Ratio (%) | 0.00 | -39.85 |
| Cash Earning Retention Ratio (%) | 0.00 | -31.23 |
| Interest Coverage Ratio (X) | 338.20 | 511.18 |
| Interest Coverage Ratio (Post Tax) (X) | 235.27 | 345.18 |
| Enterprise Value (Cr.) | 13783.39 | 18147.83 |
| EV / Net Operating Revenue (X) | 6.85 | 6.37 |
| EV / EBITDA (X) | 27.17 | 20.88 |
| MarketCap / Net Operating Revenue (X) | 6.99 | 6.51 |
| Retention Ratios (%) | 0.00 | -39.85 |
| Price / BV (X) | 16.36 | 18.28 |
| Price / Net Operating Revenue (X) | 6.99 | 6.51 |
| EarningsYield | 0.02 | 0.03 |
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Sanofi House, Mumbai Maharashtra 400072 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Aditya Narayan | Chairman & Ind.Director |
| Mr. Rodolfo Hrosz | Managing Director |
| Mr. Rachid Ayari | WholeTime Director & CFO |
| Ms. Renee Amonkar | Whole Time Director |
| Mr. Vaibhav Karandikar | Non Executive Director |
| Mrs. Usha Thorat | Independent Director |
| Mr. Rahul Bhatnagar | Independent Director |
FAQ
What is the intrinsic value of Sanofi India Ltd and is it undervalued?
As of 09 April 2026, Sanofi India Ltd's intrinsic value is ₹1714.98, which is 47.43% lower than the current market price of ₹3,262.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (43.0 %), book value (₹326), dividend yield (2.30 %), and 5-year EPS CAGR.
What is the current share price and 52-week range of Sanofi India Ltd?
Sanofi India Ltd is trading at ₹3,262.00 as of 09 April 2026, with a FY2026-2027 high of ₹6,718 and low of ₹3,151. The stock is currently near its 52-week low. Market cap stands at ₹7,513 Cr..
How does Sanofi India Ltd's P/E ratio compare to its industry?
Sanofi India Ltd has a P/E ratio of 21.7, which is below the industry average of 53.84. Trading at a steep discount to peers could signal a value opportunity or reflect concerns about the company's fundamentals.
Is Sanofi India Ltd financially healthy?
Key indicators for Sanofi India Ltd: ROCE of 57.5 % indicates efficient capital utilization; ROE of 43.0 % shows strong shareholder returns. Dividend yield is 2.30 %.
Is Sanofi India Ltd profitable and how is the profit trend?
Sanofi India Ltd reported a net profit of ₹414 Cr in Dec 2024 on revenue of ₹2,013 Cr. Compared to ₹944 Cr in Dec 2021, the net profit shows a declining trend.
Does Sanofi India Ltd pay dividends?
Sanofi India Ltd has a dividend yield of 2.30 % at the current price of ₹3,262.00. This is a relatively attractive yield for income-seeking investors.
